|Mr. Grant E. Pickering M.B.A.||Co-Founder, CEO & Director||938.36k||5.12M||1968|
|Mr. Andrew L. Guggenhime M.B.A.||Pres & CFO||716.87k||150.42k||1968|
|Mr. James Wassil M.B.A., M.S.||Exec. VP & COO||659.63k||156.8k||1969|
|Mr. Paul W. Sauer M.B.A., MBA||Sr. VP of Process Devel. & Manufacturing||525.94k||194.66k||1961|
|Mr. Harp Dhaliwal M.B.A.||Sr. VP of Commercial Manufacturing & Supply Chain||146.48k||N/A||1973|
|Dr. Ashish Khanna M.B.A., Ph.D.||Co-Founder and Chief Bus. Officer||N/A||N/A||1972|
|Dr. Jeff Fairman Ph.D.||Co-Founder & VP of Research||N/A||N/A||1964|
|Ms. Janet Graesser||VP of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Mikhail Eydelman J.D.||Sr. VP, Gen. Counsel & Corp. Sec.||N/A||N/A||1978|
|Karen Alderete||Exec. Director of HR||N/A||N/A||N/A|
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte, Inc.’s ISS Governance QualityScore as of December 1, 2022 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 9.